Carregant...
Fitxers
Embargament
Document embargat fins el 2099-01-01Tipus de document
ArticleData de publicació
Tots els drets reservats
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/172268
Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial)
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Previous midterm follow-up reports after implantation of the Absorb everolimus-eluting bioresorbable scaffold (BRS; Abbott Vascular, Santa Clara, CA, USA) in stable coronary artery disease and acute coronary syndrome have shown an increase of scaffold thrombosis leading to an excess of the device-oriented composite endpoint (DOCE: a composite of cardiac death, target vessel myocardial infarction [TVMI], and clinically driven target lesion revascularisation [CD-TLR])1. In contrast, in the six-month primary report of ABSORB STEMI: the TROFI II Study (NCT01986803)2, which randomised patients with ST-elevation myocardial infarction (STEMI) to receive either the Absorb BRS or the XIENCE metallic everolimus-eluting stent (EES; Abbott Vascular), optical frequency domain imaging (OFDI)-derived healing score was comparable between the BRS arm and the EES arm. The aim of this report was to present the three-year clinical outcome results of the BRS and the metallic EES at the time when full resorption of the scaffold device can be expected.
Matèries
Matèries (anglès)
Citació
Citació
KATAGIRI, Yuki, ONUMA, Yoshinobu, ASANO, Taku, IÑIGUEZ ROMO, Andres, JENSEN, Lisette okkels, CEQUIER FILLAT, Àngel r., HOFMA, Sjoerd h., CHRISTIANSEN, Evald h., SUTTORP, Maarten, BRUGALETTA, Salvatore, RÄBER, Lorenz, SABATÉ TENAS, Manuel, WINDECKER, Stephan, SERRUYS, Patrick w.. Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial). _Eurointervention_. 2018. Vol. 14, núm. 11, pàgs. e1224-e1226. [consulta: 8 de gener de 2026]. ISSN: 1774-024X. [Disponible a: https://hdl.handle.net/2445/172268]